The linear ANRIL transcript P14AS regulates the NF-κB signaling to promote colon cancer progression.
ANRIL
NF-κB
P14AS
UBE2D3
miR-23a-5p
Journal
Molecular medicine (Cambridge, Mass.)
ISSN: 1528-3658
Titre abrégé: Mol Med
Pays: England
ID NLM: 9501023
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
25
06
2023
accepted:
17
11
2023
medline:
4
12
2023
pubmed:
2
12
2023
entrez:
1
12
2023
Statut:
epublish
Résumé
The linear long non-coding RNA P14AS has previously been reported to be dysregulated in colon cancer, but the mechanistic role that P14AS plays in colon cancer progression has yet to be clarified. Accordingly, this study was developed to explore the regulatory functions of ANRIL linear transcript-P14AS in cancer. The expression of P14AS, ANRIL, miR-23a-5p and their target genes were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. Cell supernatants of IL6 and IL8 were measured by Enzyme linked immunosorbent (ELISA) assay. Dual-luciferase reporter assays, RNA immunoprecipitation, or pull-down assays were used to confirm the target association between miR-23a-5p and P14AS or UBE2D3. Cell proliferation and chemosensitivity of NF-κB inhibitor BAY 11-7085 were evaluated by cell counting kit 8 (CCK8). When P14AS was overexpressed in colon cancer cell lines, enhanced TNF-NF-κB signaling pathway activity was observed together with increases in IL6 and IL8 expression. The Pita, miRanda, and RNA hybrid databases revealed the ability of miR-23a-5p to interact with P14AS, while UBE2D3 was further identified as a miR-23a-5p target gene. The results of dual-luciferase reporter, RNA pull-down, and RNA immunoprecipitation experiments confirmed these direct interactions among P14AS/miR-23a-5p/UBE2D3. The degradation of IκBa mediated by UBE2D3 may contribute to enhanced NF-κB signaling in these cells. Moreover, the beneficial impact of P14AS on colon cancer cell growth was eliminated when cells were treated with miR-23a-5p inhibitors or UBE2D3 was silenced. As such, these findings strongly supported a role for the UBE2D3/IκBa/NF-κB signaling axis as a mediator of the ability of P14AS to promote colon cancer progression. These data suggested a mechanism through which the linear ANRIL transcript P14AS can promote inflammation and colon cancer progression through the sequestration of miR-23a-5p and the modulation of NF-κB signaling activity, thus highlighting P14AS as a promising target for therapeutic intervention efforts.
Sections du résumé
BACKGROUND
BACKGROUND
The linear long non-coding RNA P14AS has previously been reported to be dysregulated in colon cancer, but the mechanistic role that P14AS plays in colon cancer progression has yet to be clarified. Accordingly, this study was developed to explore the regulatory functions of ANRIL linear transcript-P14AS in cancer.
METHODS
METHODS
The expression of P14AS, ANRIL, miR-23a-5p and their target genes were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. Cell supernatants of IL6 and IL8 were measured by Enzyme linked immunosorbent (ELISA) assay. Dual-luciferase reporter assays, RNA immunoprecipitation, or pull-down assays were used to confirm the target association between miR-23a-5p and P14AS or UBE2D3. Cell proliferation and chemosensitivity of NF-κB inhibitor BAY 11-7085 were evaluated by cell counting kit 8 (CCK8).
RESULTS
RESULTS
When P14AS was overexpressed in colon cancer cell lines, enhanced TNF-NF-κB signaling pathway activity was observed together with increases in IL6 and IL8 expression. The Pita, miRanda, and RNA hybrid databases revealed the ability of miR-23a-5p to interact with P14AS, while UBE2D3 was further identified as a miR-23a-5p target gene. The results of dual-luciferase reporter, RNA pull-down, and RNA immunoprecipitation experiments confirmed these direct interactions among P14AS/miR-23a-5p/UBE2D3. The degradation of IκBa mediated by UBE2D3 may contribute to enhanced NF-κB signaling in these cells. Moreover, the beneficial impact of P14AS on colon cancer cell growth was eliminated when cells were treated with miR-23a-5p inhibitors or UBE2D3 was silenced. As such, these findings strongly supported a role for the UBE2D3/IκBa/NF-κB signaling axis as a mediator of the ability of P14AS to promote colon cancer progression.
CONCLUSIONS
CONCLUSIONS
These data suggested a mechanism through which the linear ANRIL transcript P14AS can promote inflammation and colon cancer progression through the sequestration of miR-23a-5p and the modulation of NF-κB signaling activity, thus highlighting P14AS as a promising target for therapeutic intervention efforts.
Identifiants
pubmed: 38041015
doi: 10.1186/s10020-023-00761-z
pii: 10.1186/s10020-023-00761-z
pmc: PMC10690983
doi:
Substances chimiques
NF-kappa B
0
MicroRNAs
0
Interleukin-6
0
Interleukin-8
0
Luciferases
EC 1.13.12.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
162Subventions
Organisme : National Natural Science Foundation of China
ID : 82103289
Informations de copyright
© 2023. The Author(s).
Références
Dis Markers. 2022 Feb 9;2022:8859677
pubmed: 35186169
Biochem Biophys Res Commun. 2023 Aug 6;668:42-48
pubmed: 37244033
J Biochem Mol Toxicol. 2017 Jul;31(7):
pubmed: 28117929
Mol Cancer. 2022 Mar 10;21(1):70
pubmed: 35272681
Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6194-6201
pubmed: 31364119
J Immunol. 2008 Nov 15;181(10):7002-13
pubmed: 18981120
Mol Cell. 2019 Sep 19;75(6):1243-1255.e7
pubmed: 31353209
Mol Med Rep. 2018 Dec;18(6):5256-5260
pubmed: 30280185
Minerva Med. 2022 Jun;113(3):581-582
pubmed: 34515455
Neurochem Res. 2022 Jul;47(7):2002-2015
pubmed: 35359242
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188316
pubmed: 31639408
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S37-46
pubmed: 16113098
RNA Biol. 2016;13(1):98-108
pubmed: 26618242
Cancer Res. 2021 May 1;81(9):2259-2269
pubmed: 33509939
Cancer Biol Ther. 2017 May 4;18(5):331-338
pubmed: 28402230
Biomed Pharmacother. 2017 Dec;96:14-21
pubmed: 28961506
Oncotarget. 2014 Apr 30;5(8):2276-92
pubmed: 24810364
Life Sci. 2022 Oct 1;306:120810
pubmed: 35850243
J Med Chem. 2017 Aug 24;60(16):6828-6852
pubmed: 28696694
Front Endocrinol (Lausanne). 2018 Jul 24;9:405
pubmed: 30087655
J Cell Biochem. 2018 Mar;119(3):2708-2718
pubmed: 29057547
RNA. 2019 Jan;25(1):1-16
pubmed: 30333195
Cell Rep. 2022 May 10;39(6):110813
pubmed: 35545048
Semin Immunopathol. 2009 Jul;31(2):249-56
pubmed: 19495757
Mol Cancer. 2020 Feb 27;19(1):42
pubmed: 32106863
J Bone Oncol. 2018 Feb 13;11:51-55
pubmed: 29520337
Exp Cell Res. 2017 May 15;354(2):71-77
pubmed: 28327409
Cancer Biother Radiopharm. 2021 Sep;36(7):549-555
pubmed: 32783743
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33602823
Cancer Biomark. 2018 Feb 14;21(3):613-620
pubmed: 29278879
Front Cell Dev Biol. 2022 Sep 13;10:993525
pubmed: 36176277
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3478-3484
pubmed: 31432701
Cell Res. 2011 Jan;21(1):159-68
pubmed: 21187858
Exp Cell Res. 2020 Nov 1;396(1):112280
pubmed: 32961145
Nature. 2006 May 25;441(7092):431-6
pubmed: 16724054
Cell Death Dis. 2018 Sep 5;9(9):908
pubmed: 30185771
Biosci Rep. 2018 Nov 20;38(6):
pubmed: 30279206
Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
pubmed: 25027649
J Cell Biochem. 2019 Aug;120(8):12544-12548
pubmed: 30834580
Signal Transduct Target Ther. 2020 Sep 21;5(1):209
pubmed: 32958760
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nature. 2017 Sep 7;549(7670):101-105
pubmed: 28813417
Bioengineered. 2022 Apr;13(4):10454-10466
pubmed: 35465835
J Cancer. 2021 Aug 22;12(20):6031-6049
pubmed: 34539877
Mol Med Rep. 2017 Aug;16(2):2309-2317
pubmed: 28656260